AstraZeneca: Externally Sponsored Scientific Research (ESR) – Vaccines & Immune Therapies Focus
AstraZeneca invites non-clinical and observational studies of its licensed and pipeline vaccines and immunotherapies. Focus areas include live-attenuated influenza (LAIV) transmission dynamics, bivalent RSV/hMPV VLP vaccine epidemiology, and real-world performance of RSV prophylactic antibodies in high-risk paediatric populations.
Eligibility Criteria:
-
External researchers at hospitals, universities, or research centres.
-
Proposals must use AstraZeneca vaccine platforms or generate unbranded immunological/epidemiological data.
-
Must comply with local ethics and biosafety regulations.
Funding Details:
-
Support Type: Provision of vaccine lots or antibody supply, assay development, platform access, and analytical support.
-
Substances & Interests:
-
FluMist/Fluenz (LAIV): Household and school transmission, immunological correlates of protection, delivery-model effectiveness, and adult self-administration impact.
-
IVX-A12 (RSV/hMPV VLP): Incidence, disease severity, and health-economic burden in adults ≥18 years, including high-risk comorbid cohorts and resource-utilization modelling.
-
Synagis (palivizumab): Real-world prophylaxis outcomes in children; proposals by invitation after medical-team consultation.
-
Deadline:
Rolling intake; proposal decisions within approximately 45 days.
Where to Go for Further Information:
Access the ESR tool via AstraZeneca’s Partnering → Externally Sponsored Research page. Pre-submission discussions with the Vaccines & Immunology medical team are recommended.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023